Mitomycin Accord

Mitomycin, the active ingredient in Mitomycin Accord, is an antineoplastic antibiotic (alkylating agent) presented as an injectable for intravenous use. It is employed in cancer chemotherapy to treat several solid tumours, including gastric, pancreatic, bladder and breast cancers, in adult patients. The drug works by interfering with DNA replication, leading to tumour cell death.

GNH USA supplies Mitomycin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals, pharmacies and clinics worldwide. Our distribution network ensures timely delivery and compliance with local regulatory requirements.

Mitomycin is an antineoplastic antibiotic used in chemotherapy for solid tumours. - Gastric cancer: improves disease control and may extend survival in advanced cases. - Pancreatic cancer: used in combination regimens to reduce tumour burden and enhance response rates. - Bladder cancer: administered intravesically or systemically to achieve tumour regression and prevent recurrence. - Breast cancer: incorporated into multi‑agent protocols for metastatic disease to achieve partial or complete responses.

Mitomycin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring during or after infusion. - Myelosuppression: reduced white blood cells, platelets, and red cells leading to infection risk. - Alopecia: temporary hair loss during treatment cycles. - Mucositis: inflammation of the mouth and gastrointestinal lining. - Fatigue: generalized tiredness affecting daily activities.

Serious or Rare Side Effects: - Pulmonary fibrosis: progressive scarring of lung tissue causing breathing difficulties. - Renal toxicity: impaired kidney function requiring monitoring of serum creatinine. - Severe bone‑marrow suppression: life‑threatening pancytopenia. - Hemolytic‑uremic syndrome: rare clotting disorder with kidney failure. - Anaphylactic reactions: immediate hypersensitivity requiring emergency care.

Mitomycin requires careful monitoring and patient selection to minimise risks. - Monitor blood counts: perform regular CBCs to detect myelosuppression early. - Assess renal function: check serum creatinine and urine output before each dose. - Evaluate pulmonary status: baseline lung function tests are advised for patients with pre‑existing lung disease. - Avoid use in active severe infection: postpone treatment until infection is controlled. - Use effective contraception: both male and female patients should employ reliable birth control during therapy and for a defined period afterward. - Store at controlled room temperature: keep in original container, protect from light and moisture.

Mitomycin can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Concurrent alkylating agents: additive toxicity to bone marrow and organs. - High‑dose radiation therapy: increased risk of severe tissue damage.

Moderate Interactions (Monitor Closely): - Nephrotoxic drugs (e.g., cisplatin, aminoglycosides): may exacerbate kidney injury. - Other myelosuppressive agents (e.g., methotrexate, vincristine): require close blood‑count monitoring. - Anticoagulants (e.g., warfarin, heparin): heightened bleeding tendency. - CYP450 modulators: may affect mitomycin metabolism and plasma levels.